A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act
- PMID: 25602859
- PMCID: PMC4330831
- DOI: 10.2105/AJPH.2014.302327
A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act
Abstract
Patients with chronic HCV have predictable overlapping comorbidities that reduce access to care. The Affordable Care Act (ACA) presents an opportunity to focus on the benefits of the medical home model for integrated chronic disease management. New, highly effective HCV treatment regimens in combination with the medical home model could reduce disease prevalence. We sought to address challenges posed by comorbidities in patients with chronic HCV infection and limitations within our health care system, and recommend solutions to maximize the public benefit from ACA and the new drug regimen.
Similar articles
-
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.Aliment Pharmacol Ther. 2014 Sep;40(6):657-75. doi: 10.1111/apt.12871. Epub 2014 Jul 28. Aliment Pharmacol Ther. 2014. PMID: 25065960
-
The price of good health.Nat Med. 2014 Apr;20(4):319. doi: 10.1038/nm.3538. Nat Med. 2014. PMID: 24710362
-
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.Ann Intern Med. 2015 Mar 17;162(6):407-19. doi: 10.7326/M14-1152. Ann Intern Med. 2015. PMID: 25775313
-
The rapid evolution of treatment strategies for hepatitis C.Am J Gastroenterol. 2014 May;109(5):628-35; quiz 636. doi: 10.1038/ajg.2014.66. Epub 2014 Apr 15. Am J Gastroenterol. 2014. PMID: 24732866 Review.
-
The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection.JAMA Intern Med. 2014 Jul;174(7):1170-1. doi: 10.1001/jamainternmed.2014.2151. JAMA Intern Med. 2014. PMID: 24798321 Review. No abstract available.
Cited by
-
Clinical Encounters and Treatment Initiation for Chronic Hepatitis C Patients: Applications of Adaptive Leadership Framework for Chronic Illness.Sage Open. 2019 Jan-Mar;9(1):10.1177/2158244018824461. doi: 10.1177/2158244018824461. Epub 2019 Jan 17. Sage Open. 2019. PMID: 31903296 Free PMC article.
-
Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.J Viral Hepat. 2017 Nov;24(11):955-965. doi: 10.1111/jvh.12728. Epub 2017 Aug 16. J Viral Hepat. 2017. PMID: 28815822 Free PMC article.
References
-
- Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–714. - PubMed
-
- Centers for Disease Control and Prevention. Hepatitis C information for health professionals. Available at: http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Accessed August 12, 2014.
-
- Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5):S35–S46. - PubMed
-
- Brown RS. Hepatitis C and liver transplantation. Nature. 2005;436(7053):973–978. - PubMed
-
- Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics. 2006;24(7):661–672. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
